Doi:10.1016/s0140-6736(03)13920-7

e-mail submissions to correspondence@lancet.com Mortality reduction by breast-cancer screening yield accorded with the trial results: one This article, together with other reports Julius Center for Health Sciences and Primary Care, Utrecht Medical Center, HP D 01.335, PB 85500, 3508 GA Utrecht, Netherlands(e-mail: l.bonneux@jc.azu.nl) Otto SJ, Fracheboud J, Looman CWN, et al.
mammography screening in Dutchmunicipalities and effect on breast-cancer change in (disease-free) life expectancy.
mortality: a systematic review. Lancet 2003; 361: 1411–17.
National Evaluation Team for Breast Cancer neither is the mortality reduction, which Screening. Landelijke evaluatie vanbevolkingsonderzoek naar borstkanker in 8-year period of screening, 3·13 million Nederlands, vol IX [National evaluation of population screening for screening].
Visser D, Coebergh JWW, Schouten LJ, van Dijk JAAM (eds). Incidence of cancer in the Netherlands 1997. Utrecht: Vereniging women since 1980 was rather striking.
Frisell J, Nordenskjöld B, Rutqvist LE.
Long-term effects of mammographyscreening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 909–19.
Black WC, Haggstrom DA, Welch H.
All cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002;
94: 167–73.
Sir—Suzie Otto and colleagues1conclude that changes in use ofadjuvant systemic therapy are an introduction of population-basedmammography screening in the Netherlands. They assumed that theproportion of node-positive patients Incidence of and mortality from breast cancer in women aged 50–75 years in the Before 1989, only first hospital-admissions of breast cancer as the primary diagnosis were available.
THE LANCET • Vol 362 • July 19, 2003 • www.thelancet.com For personal use. Only reproduce with permission from The Lancet.
Nordic Cochrane Centre, Rigshospitalet Dept 7112, Blegdamsvej 9, DK-2100 Copenhagen,Denmark Adri C Voogd, Jan Willem W Coebergh municipalities and effect on breast-cancer University, PO Box 616, 6200 MD Maastricht, mortality: a systematic review. Lancet 2003; 361: 1411–17.
Registry, Comprehensive Cancer Centre South, La Vecchia C. Cancer mortality in Europe,1990–1994, and an overview of trends from 1955 to 1994. Eur J Cancer 1999; 35:
Levi F, Lucchini F, Negri E, La Vecchia C.
municipalities and effect on breast-cancer The fall in breast cancer mortality in
Europe. Eur J Cancer 2001; 37: 1409–12.
mortality: a systematic review. Lancet 2003;
361: 1411–17.
handbooks of cancer prevention. Volume 7: breast cancer screening. Lyon: IARC Press, cancer in southeast Netherlands since 1984: when tumours were receptor-positive.
a population-based study. Acta Oncol 1994;
33: 753–57.
Frisell J, Nordenskjöld B, Rutqvist LE.
screening: updated overview of the Swedish randomised trials. Lancet 2002; 359:
Louwman WJ, Klokman WJ, Coebergh JW.
Excess mortality from breast cancer 20 years normal. Br J Cancer 2001; 84: 700–03.
guidelines for adjuvant systemic treatment of breast cancer at hospital level [in Dutch].
Ned Tijdschr Geneeskd 2000; 144: 1572–74.
for screening between 1991 and 1996.
endocrine treatment is difficult. A later those aged 50–69 years (16·3% vs THE LANCET • Vol 362 • July 19, 2003 • www.thelancet.com For personal use. Only reproduce with permission from The Lancet.

Source: http://www.digitaalprotest.nl/uploaded/bibliotheek_upload_document/1163/Coebergh_19072003.pdf